Antibody-Based Therapeutics Against COVID-19

A special issue of Antibodies (ISSN 2073-4468).

Deadline for manuscript submissions: closed (20 September 2021) | Viewed by 3439

Special Issue Editor

Center for Antiviral Research, Wuhan Institute of Virology (WIV), Chinese Academy of Sciences, 262 Jinlong Street, Jiangxia, Wuhan 430207, China
Interests: phage display; yeast display; B cell immortalization; vaccine design by epitope analysis; Fc fragments
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

An emerging coronavirus, termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causes the disease known as COVID-19. To date, SARS-CoV-2 continues to rapidly spread globally and seriously threaten public health. Therapeutic antibodies are shown to be very effective in the treatment of various diseases, including viral infection and immune disorder. Clinical trials with antibody-based drugs for COVID-19 are being performed all over the world. Some of them are quite promising. For example, Bamlanivimab, a neutralizing antibody against SARS-CoV-2, was authorized by the FDA for the treatment of COVID-19 in high-risk patients on November 9, 2020. This Special Issue will collect the last progress on antibody-based therapeutics against COVID-19 from bench to bedside.

Prof. Dr. Rui Gong
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • SARS-CoV-2
  • COVID-19
  • antibody
  • viral infection
  • immune disorder

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 1482 KiB  
Communication
Immune Maturation Effects on Viral Neutralization and Avidity of Hyperimmunized Equine Anti-SARS-CoV-2 Sera
by Myriam Belén González Viacava, Augusto Varese, Ignacio Mazzitelli, Laura Lanari, Lucía Ávila, María Julia García Vampa, Jorge Geffner, Osvaldo Cascone, José Christian Dokmetjian, Adolfo Rafael de Roodt and Matías Fingermann
Antibodies 2022, 11(1), 3; https://0-doi-org.brum.beds.ac.uk/10.3390/antib11010003 - 02 Jan 2022
Cited by 1 | Viewed by 2784
Abstract
Mass-vaccination against COVID-19 is still a distant goal for most low-to-middle income countries. The experience gained through decades producing polyclonal immunotherapeutics (such as antivenoms) in many of those countries is being redirected to develop similar products able to neutralize SARS-CoV-2 infection. In this [...] Read more.
Mass-vaccination against COVID-19 is still a distant goal for most low-to-middle income countries. The experience gained through decades producing polyclonal immunotherapeutics (such as antivenoms) in many of those countries is being redirected to develop similar products able to neutralize SARS-CoV-2 infection. In this study we analyzed the biological activity (viral neutralization or NtAb) and immunochemical properties of hyperimmune horses’ sera (HHS) obtained during initial immunization (I) and posterior re-immunization (R) cycles using the RBD domain of the SARS-CoV-2 spike protein as antigen. HHS at the end of the R cycle showed higher NtAb titers when compared to those after the I cycle (35,585 vs. 7000 mean NtAb, respectively). Moreover, this increase paralleled an increase in avidity (95.2% to 65.2% mean avidity units, respectively). The results presented herein are relevant for manufacturers of these therapeutic tools against COVID-19. Full article
(This article belongs to the Special Issue Antibody-Based Therapeutics Against COVID-19)
Show Figures

Figure 1

Back to TopTop